Allogeneic myeloablative transplantation for patients aged 50 years and over.

摘要: Allogeneic hematopoietic stem cell transplantation (HSCT) has been performed mainly for young patients due to concern about the high incidence of treatment-related mortality (TRM). Recent advances reduce TRM by using peripheral blood cells or nonmyeloablative conditioning regimens have increased age limit this procedure, and correctly identifying indication transplant is essential older patients. In study, we analyzed data from 398 aged 50 over selected 5147 patients, who received conventional allogeneic HSCT (c-HSCT). Patients showed inferior outcomes overall survival (OS). Mulitivariate analyses confirmed that an was independent risk factor (P<0.0001) OS (P<0.0001). Among older, increasing remained adverse (P=0.0213). Regimens including total-body irradiation (TBI) correlated with a higher lower (P=0.0095 0.0303, respectively). These findings indicate c-HSCT should be offered years only if acceptable, non-TBI regimen preferable when performed.